2-(phenylmethyl)-1-naphthol has been researched along with isoliquiritigenin in 1 studies
| Studies (2-(phenylmethyl)-1-naphthol) | Trials (2-(phenylmethyl)-1-naphthol) | Recent Studies (post-2010) (2-(phenylmethyl)-1-naphthol) | Studies (isoliquiritigenin) | Trials (isoliquiritigenin) | Recent Studies (post-2010) (isoliquiritigenin) |
|---|---|---|---|---|---|
| 9 | 0 | 0 | 472 | 2 | 324 |
| Protein | Taxonomy | 2-(phenylmethyl)-1-naphthol (IC50) | isoliquiritigenin (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 1.87 | |
| Interstitial collagenase | Homo sapiens (human) | 0.016 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.269 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 0.01 | |
| Stromelysin-1 | Homo sapiens (human) | 0.081 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.269 | |
| Matrilysin | Homo sapiens (human) | 0.008 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.269 | |
| Aromatase | Homo sapiens (human) | 3.8 | |
| 17-beta-hydroxysteroid dehydrogenase type 1 | Homo sapiens (human) | 2.83 | |
| Matrix metalloproteinase-9 | Homo sapiens (human) | 0.01 | |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | 0.32 | |
| Proteasome subunit beta type-5 | Homo sapiens (human) | 4.88 | |
| 17-beta-hydroxysteroid dehydrogenase type 2 | Homo sapiens (human) | 0.36 | |
| Collagenase 3 | Homo sapiens (human) | 0.014 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.269 | |
| NACHT, LRR and PYD domains-containing protein 3 | Homo sapiens (human) | 1.54 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Izumi, A; Matsumoto, H; Miki, T; Nihro, Y; Satoh, T; Sogawa, S; Ueda, H | 1 |
1 other study(ies) available for 2-(phenylmethyl)-1-naphthol and isoliquiritigenin
| Article | Year |
|---|---|
3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Arachidonic Acid; Cell Line; Chalcone; Chalcones; Cyclooxygenase Inhibitors; Edema; Lipid Peroxidation; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred ICR; Molecular Structure; Sheep; Structure-Activity Relationship | 1993 |